Position in LFCR
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$462,273
-$5,517 QoQ
Shares Held
88,052
-30.0% QoQ
Ownership
0.233%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#27
of 98 holders
Holding Since
Jun 2020
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LFCR Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026GSA CAPITAL PARTNERS LLP holds $11,914,926 across 21 Drug Manufacturers - Specialty & Generic names. LFCR ranks #11 (3.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INDV |
Indivior Pharmaceuticals, Inc.
|
55,201 | $2,264,897 | |
| 2 | ZTS |
Zoetis Inc.
|
18,470 | $1,327,254 | |
| 3 | IRWD |
Ironwood Pharmaceuticals Inc
|
259,512 | $1,092,545 | |
| 4 | BCRX |
Biocryst Pharmaceuticals Inc
|
90,210 | $902,100 | |
| 5 | LQDA |
Liquidia Corp
|
10,098 | $805,113 | |
| 6 | KNSA |
Kiniksa Pharmaceuticals International, plc
|
11,219 | $717,455 | |
| 7 | AMLX |
Amylyx Pharmaceuticals, Inc.
|
39,241 | $704,768 | |
| 8 | XERS |
Xeris Biopharma Holdings, Inc.
|
82,830 | $656,013 |
All Filings in LFCR
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $462,273 | 88,052 | Shares | Sole | 2026-08-06 | |
| 2026-03-31 | $467,790 | 125,750 | Shares | Sole | 2026-05-08 | |
| 2025-12-31 | $677,254 | 82,794 | Shares | Sole | 2026-02-06 | |
| 2022-12-31 | $129,379 | 19,966 | Shares | Sole | 2023-02-13 | |
| 2022-09-30 | $136,994 | 15,410 | Shares | Sole | 2022-11-14 | |
| 2021-09-30 | $370,210 | 40,153 | Shares | Sole | 2021-11-12 | |
| 2020-12-31 | $256,125 | 23,606 | Shares | Sole | 2021-02-03 | |
| 2020-09-30 | $465,967 | 47,939 | Shares | Sole | 2020-11-06 | |
| 2020-06-30 | $116,247 | 14,604 | Shares | Sole | 2020-08-11 | |
| No filing history on record for this holder in this stock. | ||||||